THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY;CHAN ZUCKERBERG BIOHUB, INC.
发明人:
CLARKE, MICHAEL F.,HSIEH, ROBERT W.
申请号：
CA3075784
公开号：
CA3075784A1
申请日:
2018.09.18
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The invention is directed to methods of treating TNBC in a patient by administering to the patient an agent that inhibits the expression or activity of cyclin-dependent kinase 19 (CDK19). In some embodiments, the agent may be a small molecule inhibitor, a polynucleotide (e.g., shRNA. siRNA), or a protein (e.g., an antibody). In some embodiments, the agent does not inhibit the activity or expression of CDK8.
